duced by unilateral renal artery stenosis) showed that the stenotic kidney develops a progressive deterioration of hemodynamics, filtration, and tubular function, accompanied by a significant vascular rarefaction and the development of albuminuria, glomerulosclerosis, and tubuleinterstitial fibrosis [6] [7] [8] [9] .
There is a significant systemic and renal upregulation of the endothelin (ET) system in this model of RVD. The ET system includes 3 major isoforms: ET-1, ET-2, and ET-3, which exert their actions through specific ET-A and ET-B receptors. ET-1 is the major isoform of the ET family and plays important physiological roles in controlling renal function and blood pressure. However, it has been shown to be highly active in pathological situations and a major contributor to renal injury in atherosclerosis [10, 11] , diabetes [12, 13] , and RVD [8, 14] . Indeed, we showed that upregulation of the ET-1/ET-A pathway can lead to progressive renal dysfunction, fibrosis, and microvascular damage of the stenotic kidney in RVD, and such deleterious changes were largely attenuated by specific ET-A but not ET-B receptor antagonism [8, 14] . However, the potential mechanisms of this distinct ET-A antagonism-induced renoprotection are not fully elucidated.
Podocytes are terminally specialized epithelial cells that are key components of the glomerular filtration barrier. Damage and even loss of podocytes have been described in hypertensive-induced renal injury [15, 16] , pre-eclampsia [17] , and diabetes [18] . A major factor for podocyte health and function is vascular endothelial growth factor (VEGF). Podocytes are both sources and targets of VEGF in autocrine and paracrine fashion, express VEGF receptors [19] and also express ET-A and ET-B receptors [20] . Our recent studies showed that the excretion of nephrin from the stenotic kidney (a marker suggestive of podocyte injury) is exacerbated in the swine model of RVD but is reduced by ET-A antagonism [9] . Furthermore, the stenotic kidney has a significant decrease in the expression and availability of VEGF [21, 22] that is largely restored after ET-A antagonism [8, 9, 14] . Therefore, the current study was designed to test the hypothesis that renoprotection by ET-A antagonism may be driven by a distinct protection on podocytes steered by recovering VEGF bioavailability. To test our hypothesis and extend our previous in vivo findings [8, 9] by elucidating potential mechanisms of ET-1/ET-A-mediated podocyte injury and protection, human podocytes that were chronically exposed to hypoxia (to mimic the stenotic kidney environment in RVD [23] ) were treated with specific ET-A or ET-B antagonists. In addition, to determine whether the protection of podocytes by ET-A antagonism is mediated by VEGF, a separate similar set of experiments was carried out after VEGF blockade.
Results

Podocyte Phenotype
Since cells were used after 7-12 passages, we first determined whether cells still have podocyte characteristics. Homogenates from normoxic cells collected at the 0-hour time-point were used to determine the expression of Wilms' tumor (WT)-1 [24] by western blot (duplicates), showing preserved expression of this podocyte marker ( fig. 1 ).
Podocyte Counts
Cell counting after 96 h showed that hypoxia induced a significant reduction in the number of podocytes. Cell number was improved by ET-A but not ET-B antagonism. The average number of cells per ml in each group (mean ± SD) at the 96-hour time-point was as follows: normoxic: 9.3 × 10 6 ± 2.7 × 10 6 ; hypoxic: 4.6 × 10 6 ± 1.9 × 10 6 ; hypoxic + ET-A: 5.3 × 10 6 ± 1.9 × 10
6
, and hypoxic + ET-B: 2.9 × 10 6 ± 3.3 × 10
5
.
Hypoxia Increases ET-1 and Reduces Podocyte Activity
Hypoxia increased the concentration of ET-1 in media compared to normoxic cells (0.29 ± 0.00 vs. 0.31 ± 0.00 pg/μg, respectively, p < 0.05 vs. normoxic). ET-A antagonism did not increase ET-1 (0.27 ± 0.02 pg/μg), whereas ET-B antagonism resulted in a further increase in ET-1 WT-1 expression is preserved in podocytes after 7-12 passages, indicating preserved podocyte characteristics. Cell homogenates from normoxic podocytes were used and their expression determined in duplicates by western blotting. concentration (0.35 ± 0.00 pg/μg, p < 0.05 vs. normoxic and hypoxic). Quantification of VEGF in cell media showed that ET-A antagonism improved VEGF secretion (suggesting preserved podocyte activity), whereas hypoxic and ET-B antagonists-treated podocytes showed a similar reduction in VEGF (compared to normoxic cells after 96 h; fig. 2 A) . Furthermore, concentration of s-Flt1 was similar in the media of normoxic, hypoxic and ET-A antagonist-treated podocytes but progressively upregulated in media from ET-B antagonists-treated ones ( fig. 2 B) .
ET-A Blockade Restore the Expression of Podocin, Nephrin, and Angiogenic Factors
Hypoxic and ET-B-treated podocytes showed a decreased expression of VEGF, which was preserved by ET-A antagonism. In addition, ET-A antagonism improved the expression of podocin (analysis of variance (ANOVA), p < 0.01) and nephrin, which are both major podocyte slit diaphragm-associated proteins [19, 25] , implying an overall reduction in hypoxia-induced podocyte damage that was not fully achieved after ET-B antagonism ( fig. 3 A, B) . 
ET-A Blockade Improved Expression of Apoptotic and Survival Factors
A proteome profiler apoptotic array showed the following factors with a higher expression in hypoxic podocytes compared to normoxic controls: BAX, p53, SMAC, heat-shock protein (HSP) 60, cytochrome (Cyt)-C and apoptosis-induced factor (AIF). The differences in the expression of these factors were then confirmed by western blot and showed a significant attenuation by ET-A antagonism (ANOVA, p < 0.05 for all). ET-A blockade also improved the expression of pro-survival p-Akt (ANOVA, p = 0.02) and Bcl-2 (ANOVA, p = 0.04), suggesting a decrease in apoptotic activity. Interestingly, ET-B antagonism resulted in a similar or higher expression of apoptotic and survival factors as observed in hypoxic cells, indicating a non-protective effect on hypoxic podocytes ( fig. 4 A) . These changes in expression of apoptotic and survival factors (and cell counts) were accompanied by modifications in podocyte morphology (nuclear condensation/fragmentation) suggestive of apoptosis ( fig. 4 B) .
VEGF-NA Abolished the Beneficial Effects of ET-A Blockade on Podocyte Survival
To determine whether VEGF plays a role in ET-A-induced protection of podocytes, a separate similar set of experiments were performed after the incubation of podocytes to VEGF-neutralizing antibody (VEGF-NA). 
Discussion
Podocytes are increasingly recognized as a major target of ET-A receptor blockers. Preservation of podocyte integrity and function has been suggested as a central mechanism behind the improvements in proteinuria in CKD patients treated with ET-A antagonists, regardless of the etiology [26] . The current study extends our previous findings on the therapeutic efficacy of ET antagonists on the stenotic kidney in chronic RVD. Using a hypoxic in vitro setting, we observed that podocytes exposed to chronic hypoxia (as occurs in the stenotic kidney [23] ) are progressively damaged, a process that may be partly driven by a sustained decrease in VEGF and accelerated apoptosis. ET-A antagonism significantly improved podocyte survival, preserved VEGF bioavailability, and decreased apoptotic signaling, effects that were not observed after ET-B blockade or VEGF-NA. Therefore, our study suggests that preservation of VEGF is a prominent mechanism by which ET-A antagonism protects the integrity and survival of podocytes in the ischemic kidney. These findings contribute to the understanding of ET-A-induced renoprotection that is consistently observed in several pre-clinical and clinical studies; they in turn also support the notion of VEGF as a potential therapeutic target to protect the kidney.
Podocytes are the major components of the glomerular filtration barrier. Quantification of podocytes in urine has been proposed as a marker of renal injury [27] since damage and loss of podocytes may reflect the severity of glomerular disease. Podocytes are terminally differentiated epithelial cells and it is still not fully clear whether their regeneration or proliferation occur once they are severely damaged [20] . However, emerging evidence suggest that several therapeutic interventions that recover renal function are mainly driven by podocyte protection [26, 28] , indicating that podocytes may be a therapeutic target for repair and recovery. Among these interventions is the use of antagonists of the ET receptors. Podocytes have a fully functional ET system and express both ET-A and ET-B receptors [29] . Previous studies have shown that podocytes can generate and secrete ET-1 in vitro as, exposure of podocytes to ET-1 induces a disruption of their cytoskeleton [30, 31] . Recent preclinical and clinical studies support the notion that ET-A antagonism reduces proteinuria in CKD possibly by improving podocyte health [32] . Our previous studies in a swine model of RVD demonstrated that the ET-1/ET-A pathway is upregulated and it plays a prominent pathophysiological role in deteriorating RBF and GFR as well as in promoting inflammation and fibrosis [8, 9, 14] . Furthermore, blunted GFR and glomerulosclerosis in this model are associated with increased excretion of nephrin and attenuated expression of podocin, suggesting substantial podocyte damage. However, the mechanisms of ET-A mediated podocyte damage and protection are unclear.
Our results extend our previous in vivo studies [8, 9, 14] by elucidating potential underlying mechanisms of podocyte protection by ET-A antagonism. We first observe that the blockade of the ET-A, but not ET-B receptors improved the release of VEGF by podocytes under hypoxia to a greater extent. Indeed, untreated and ET-B antagonisttreated hypoxic podocytes showed a smaller VEGF production (compared to normoxic) after 96 h. Although hypoxia may serve as a powerful stimulus for release of VEGF, this may be the case in the early phase but not when hypoxia in renal cells is sustained; this finding concurs with studies from our and other laboratories on in vivo and in vitro settings [33, 34] . This may be partly driven by the alteration of the hypoxia-induced factor-1α/VEGF axis combined with possible loss or exhaustion of VEGF sources [22, 35] . VEGF is a pivotal cytokine used for the maintenance and generation of the vascular networks by mediating endothelial cell differentiation, survival, proliferation, and migration toward formation of new vessels and vascular repair [36] . Importantly, podocytes are one of the major sources of renal VEGF and present fully functional VEGF receptors [19, 37, 38] . VEGF is also necessary for podocyte survival and function via interaction with nephrin through VEGFR2, which together with podocin are crucial slit-diaphragm associated proteins for podocyte integrity. Loss of VEGF in the advanced stage of renal disease is thought to be driven by the loss of podocytes [39, 40] , underscoring the importance of VEGF for renal health. Our study shows that VEGF bioavailability and expression is improved after ET-A but not ET-B antagonism, accompanied by restored expression of podocin and nephrin. Furthermore, the generation of s-Flt1, which acts as a VEGF 'trap' thus reducing the availability of VEGF and its effects [41] , was dramatically increased after ET-B antagonism, indicating that the blockade of ET-B receptors does not lead to protection of podocytes and may further compromise their survival. The s-Flt1 receptor has important physiological functions in guiding VEGF effects in vascular sprouting [42] for example, but also has been implicated in the pathophysiology of pre-eclampsia [43] and CKD [44] when it is elevated. Therefore, our data may extend our recent studies by offering a potential mechanistic explanation for the deleterious effects of single ET-B antagonism in the stenotic kidney of the swine model of RVD [8] . In line with these observations, cell counts were improved only after ET-A antagonism, underscoring a potentially important role of VEGF on podocyte viability. Hypoxia is a powerful stimulus for renal apoptosis [45, 46] , and we showed that the ET-1/ET-A pathway contributes to apoptosis in the stenotic kidney [14] . Our study shows that hypoxic podocytes have increased expression of pro-apoptotic factors such as AIF, BAX, p-53, and SMAC, suggesting that hypoxia may stimulate both caspase-independent and -dependent pathways [47] [48] [49] . We also observed that hypoxia increased Cyt-C, a factor necessary for activation of apoptosis especially when coupled with BAX [50] , which was also elevated. Hypoxia also blunted the expression of pro-survival p-Akt, although anti-apoptotic Bcl-2 was upregulated, possibly reflecting a potential (but likely insufficient) mechanism to counteract the enhanced pro-apoptotic activity. The increased expression of pro-apoptotic mediators (and reduction in cell counts) was accompanied by changes in podocyte morphology suggestive of apoptotic cell death (e.g. nuclear condensation and fragmentation [51, 52] ). Notably, most of these changes were restored only by ET-A antagonism, whereas the expression of all the pro-apoptotic factors was further increased by ET-B blockade.
Our study strongly suggests that the blockade of the ET-A receptors may protect podocytes by preserving VEGF activity after performing a series of experiments after VEGF-NA. The use of VEGF inhibitors is among the first line of therapy in some types of cancer. However, VEGF inhibition carries significant renal damage, proteinuria, and hypertension, underscoring the prominent role of VEGF in the kidneys [53] . It is possible that some of these deleterious effects are driven by accelerated loss of podocyte since we observed that VEGF-NA further decreased cell counts and increased the expression of some of the pro-apoptotic factors in hypoxic podocytes. More importantly, these effects were also observed after ET-A receptor blockade, suggesting that the beneficial effects of ET-A antagonism on podocytes are largely dependent on VEGF bioavailability. These findings offer a mechanistic explanation and a pathophysiological link between renal dysfunction, damage, and the loss of VEGF that were recovered after chronic ET-A (but not ET-B) antagonism in the swine model of chronic RVD [8, 9] .
Our study has some limitations. Although the in vitro setting offers an opportunity to elucidate mechanisms, we are aware that the degree of hypoxia was relatively severe and of short duration, which may not reflect the level of renal hypoxia or its full development and pathophysiological consequences in the stenotic kidney. It is also possible that other factors not investigated in this study may play a role in causing podocyte damage in addition to the loss of VEGF, such as transforming growth factor-β [54] , which has a powerful anti-angiogenic and pro-fibrotic effect [55] and, as we have shown, was upregulated in the stenotic kidney but attenuated by ET-A blockade [8] . Nevertheless, our study represents a mechanistic extension of our in vivo studies that showed the therapeutic efficacy of clinically available ET-A antagonists for renoprotection in RVD [8, 9] . Furthermore, since podocytes are a central component of the glomerular filtration barrier and due to the vital role that VEGF plays in podocyte health, a mechanistic understanding of their protection by ET-A antagonists may open new avenues for future research to protect the kidney that may go beyond RVD and contribute to the treatment of other forms of chronic renal disease.
Methods
All experiments and measurements were performed in triplicates.
Podocyte Cell Culture Protocol
All experiments were carried out using aseptic techniques. All culturing of the human podocytes was performed as per guidelines from Celprogen Inc., Calif., USA. Media was acquired from Celprogen and it contained all growth factors and nutrients necessary for culturing and sub-culturing human podocyte primary cells. Experiments were carried out with cells from passage 7 to 12. Expression of WT-1 was measured by western blot before the initiation of the experiments to determine whether cells preserved podocyte characteristics.
Cell Culture
Human podocytes were obtained from Celprogen Inc., Torrance, Calif., USA (cat #E36036-08). Cells were thawed in 37 ° C water bath and 500 μl of warmed human podocyte complete growth media was added. A complete growth media made specifically for the proliferation and culturing of human podocytes (Celprogen Inc., Torrance, Calif., USA, cat #M36036-08S) that contains 10% fetal bovine serum as well as a standard mixture of penicillin and streptomycin (10,000 U/ml) was used. The cells were gently re-suspended and transferred to a 15 ml conical tube, a process that was repeated 2 more times to ensure full transfer. Cells were then centrifuged for 5 min at 100 g , supernatant was discarded, and cells resuspended in 500 μl of media and transferred to a T75 flasks coated with human podocyte cell culture extracellular matrix (ECM; Celprogen Inc., Torrance, Calif., USA, cat #E36036-08-T25 or T75). Cells were then allowed to grow to >80% confluency in 5% CO 2 and 19% O 2 water-jacketed incubator at 37 ° C before splitting in a 1: 3 ratio to ensure enough viable cells for the experiments, as per company guidelines.
We distributed in equal concentrations into 110 flasks. Briefly, cells were then divided for proliferative purposes and at the time 81 of experimentation, the cells were at passage 9-10 and morphology of cells was monitored throughout (sub-culturing). Cells were washed twice with 1× PBS for 3 min each and incubated in 5 ml of 0.05% trypsin for 5 min or until they were fully detached. Five hundred microliters of fresh media were added and supernatant was transferred to a 10 ml conical tube and centrifuged at 100 g for 5 min. Supernatant was removed and cells then re-suspended in 3 ml of media. One milliliter was transferred into an ECM-coated T75 flask containing 9 ml of warmed human podocyte complete growth media with serum and antibiotics.
Cells were grown to >80% confluency in ECM-coated T75 flasks. Cells were washed twice with 1× PBS for 3 min and then 5 ml of 0.05% trypsin added to release the cells from the flask. The flasks were incubated at 37 ° C for 5 min and trypsinization was stopped by the addition of 5 ml of serum-enriched growth media and cell suspension transferred into a 15 ml conical tube and centrifuged at 100 g for 5 min. Supernatant was removed from the conical tube and cells were re-suspended in 5 ml of growth media for distribution into new ECM-coated flasks for experimentation. Then, 500 μl of cell suspension was added to an ECM-coated T25 flask along with 7.5 ml of media.
Cell Counting Cells were washed twice with 1× PBS for 3 min each and incubated in 5 ml of 0.05% trypsin for 5 min or until they were fully detached. Five hundred microliter of fresh media were added and supernatant was transferred to a 10-ml conical tube and centrifuged at 100 g for 5 min. The cell supernatant was discarded and cells were suspended in 100 μl of media. To this, 10 μl of trypan blue 0.04% (Fisher Scientific) was added. Ten microliters of the cell suspension were then added on to a hemocytometer and 4 areas were counted and averaged in each sample, and multiplied by 10/11 dilution factor to correct for the cell to trypan ratio and then by 10 4 to find cells per ml, as described [56] . This was done to the 0-hour control and in all 96-hour cell groups. This process was carried out within 5 min of detaching the cells from growing flasks to reduce the reduction of cell viability. The cells were then centrifuged for 5 min and supernatant was removed. Cells were then lysed in the same way as the other groups. All cell counts for each square were above 100. Very few dead or dying cells were seen possibly due to the dead cells releasing from the flask or being removed during the washing process. An average of 4 fields per sample was used for cell counting and expressed as mean ± SD (see the Results section). All cell groups were counted in this manner.
Experimental Protocol
General Characteristics A total of 110 flasks of cells were created; 108 flasks were used for the experiments and 2 were used for cell count at 0-hour. Cells were incubated overnight, allowing them to attach to the flasks before the media was changed. Flasks were then randomly designated as hypoxic injury or normoxic cells after overnight incubation.
Hypoxic Injury Normoxic conditions were generated by the incubation of the cells at 5% CO 2 with 19% O 2 , whereas severe hypoxic conditions were generated by the incubation of the cells at 5% CO 2 and 1% O 2 . Oxygen levels were controlled using nitrogen gas injection in accordance with previous protocols [57] .
Treatment with ET-Receptor Antagonists
We first performed a pilot study to determine the dose of ET antagonist to be used in our experiments. Dosage was determined after performing a cell-survival experiment using concentrations of 1, 0.1, and 0.01 mg/ml of either ET-A or ET-B antagonist. This study allowed us to determine that the concentration of ET-A or ET-B antagonists of 1 and 0.1 mg/ml were unsuitable for the experimentation due to significant decreased cell-count and low protein content at time points of interest. Cells were observed under normoxic and hypoxic conditions for 1, 24, and 96 h to determine the point when the cells became nonviable. These experiments required 48 flasks of cells. The cells were collected and lysed using 0.0125% Triton X. The protein content of each was analyzed using a standard bicinchromatic acid (BCA) protein assay kit (Fisher Thermoscientific Product #23227).
After the identification of the appropriate dose, hypoxic and normoxic groups were subsequently split into control, treated with ET-A antagonist, or treated with ET-B antagonist. ET-A (ABT-627, atrasentan) and ET-B (A-192621) antagonists (Abbvie, North Chicago, Ill., USA) were suspended in 10% DMSO and 90% DI water to a final concentration of 10 mg/ml, DMSO was added to the solutions in order to make the antagonists soluble. Drug suspension with a volume of 7.5 μl was added to each flask to bring the final drug concentration per flask to 0.01 mg/ml. These experiments required 21 flasks of cells (20 for the experiments and 1 for the cell count at baseline).
Addition of VEGF-NA In a separate set of experiments following the above protocols, additional groups were incubated with a VEGF-NA (R&D Systems, AF-293-NA). The purpose of these studies was to determine whether ET-A blockade protects podocytes by restoring VEGF bioavailability. Anti-VEGF antibody was reconstituted according to instructions included with antibody. Anti-VEGF antibody was added to a final concentration of 0.1 μg/ml of cell culture media, as previously shown [58] . Groups were as follows: normoxic, normoxic + VEGF-NA treated, hypoxic, hypoxic + VEGF-NA treated, hypoxic ET-A treated, hypoxic ET-A + VEGF-NA treated, hypoxic ET-B treated, and hypoxic ET-B + VEGF NA treated. These experiments required 41 flasks (40 for the experiments and 1 for the cell count at baseline). Cell homogenates and supernatant were collected as before at 1, 24, and 96 h and stored at -80 ° C.
The treatments with ET receptor antagonists and the addition of VEGF-NA were performed using a one-time dose. This strategy was decided to reduce chances of variability, keep total DMSO concentration low, to have the ability to quantify total soluble factors produced during the study, and to account effects of soluble markers produced during drug induction and hypoxic injury.
Podocyte Counts
To determine the impact of hypoxia and treatments, cell counting was performed in all groups at 0 (the average original number of plated podocytes for all the groups: 2.6 × 10 7 ) and 96 h for comparisons.
Images of cells were taken at the 96-hour time point (×100) before being counted and lysed. Only one time point was chosen to image in order to reduce the amount of time the groups spent outside of their hypoxic or normoxic environments and reduce the chance of variability due to temperature change or infection. The 0-and 96-hour groups were re-suspended in 1 ml of media and 100 μl of trypan 82 blue 0.04% (Fisher Scientific). Cells were counted using a hemocytometer following an established protocol [56] and as we previously described [33] . Following counting, cells were centrifuged and lysed by adding 1 ml of 0.0125% Triton X to each cell pellet.
Sample Collection
Baseline or 0-hour for the experiment for all groups was considered the time at which the ET-A or ET-B antagonists were introduced. Time points of 1, 24 and 96 h after drug introduction were collected in order to determine the time-dependent changes in podocyte number and subsequent expression or concentration of apoptotic and survival factors, as described below. Cell supernatant and homogenates were collected from each group at 1, 24, and 96 h after drug introduction. In general, 1 and 24 were chosen to show how quickly the cells began to decline after hypoxic insult. The 96 h time point was chosen to show an exacerbation of hypoxic injury over an extended period. Samples were then transferred to microcentrifuge tubes and stored at -80 ° C for subsequent measurement of protein expression via western blot or concentration of growth factors via enzyme-linked immunosorbent assay (ELISA).
Proteome Profiler Arrays
In order to determine whether and how the apoptotic cascade plays a role in hypoxia-induced podocyte damage and how ET antagonism may protect podocytes, a Proteome Profiler Human Apoptosis Array Kit (R&D Systems, Minneapolis, Minn., USA, cat #ARY009) was obtained to identify apoptotic factors. Two control and 2 treated groups were chosen: normoxic 72-hour control, hypoxic 72-hour control, hypoxic ET-A-treated 72-hour group, and hypoxic ET-B 72-hour-treated group. The 72-hour time point was chosen in order to comply with each kit's recommended minimum protein loading. All reagents and membranes were provided with each kit and the experiment performed following vendors' instructions.
Briefly, membranes were blocked using the blocking buffer provided with the kit for 1 h on the bench top at room temperature, then washed 3 times (using kit's buffer), and 250 μg of protein was loaded into each well and incubated overnight at 4 ° C on a shaker plate. After overnight incubation, a secondary antibody cocktail was reconstituted and membranes incubated for 1 h at room temperature, then washed 3 times and then incubated in streptavidinhorseradish peroxidase (HRP) for 30 min at room temperature. After a single wash, membranes were incubated for 1 min in a chemiluminescence reagent mix and then developed. Biomarkers that expressed the highest were then quantified by western blot as described below.
Western Blotting Total protein concentration of each sample was determined by BCA, as previously described [7] . A Bio-Rad Criterion TGX Precast Gel Any Kd or 18% agarose (if the target molecular weight was low) were then loaded with samples of 8 μg of total protein with 4× reducing Laemmli SDS-sample buffer (Boston Bio Products, Ashland, Mass., USA, cat #BP-110R). Gels were run using the Bio-Rad criterion cell (Bio-Rad, Hercules, Calif., USA, cat #165-6001) at 100 V for 1 h or until adequate separation was achieved. Gels were removed and transferred to nitrocellulose using criterion blotter (Bio-Rad, Hercules, Calif., USA, cat #170-407) at 100 V at 4 ° C for 45 min. Nitrocellulose membranes were incubated in Ponceau S solution (Sigma Aldrich, St. Louis, Mo., USA, cat #P7170) to visual total protein and to assess transfer.
Membranes were washed using tris buffered saline with 0.1% volume/volume tween (TBST) added and blocked using 5% weight/volume nonfat dry milk reconstituted in TBST. All primary and secondary antibodies were diluted using 5% nonfat dry milk. Primary antibodies for VEGF, podocin, nephrin, pro-apoptotic AIF, BAX, p53, SMAC, Cyt-C, and HSP60, and anti-apoptotic p-Akt and Bcl-2 (Santa Cruz Biotechnologies, Santa Cruz, Calif., USA) were used. All primary antibodies were diluted to 1: 200 in 5% milk and incubated overnight in 4 ° C. β-actins was used as a loading control and diluted 1: 500 in 5% milk and incubated at 1 h at room temperature or overnight at 4 ° C. The following day, membranes were washed 3 times in TBST followed by incubation with goat anti-rabbit or anti-mouse IgG conjugated to HRP for 1 h diluted to 1: 5,000 (Santa Cruz Biotechnologies, Calif., USA). After 1 h incubation gels were washed 3 times in TBST, and SuperSignal West Pico chemiluminescent substrate (Fisher Thermoscientific Products, cat #34078) was added based on manufacturer's instructions for 3-5 min. Membranes were developed using Carestream Kodak BioMax light film (Sigma-Aldrich, St. Louis, Mo., USA, cat #8194540) with exposure lengths varying from 1 to 20 min. Protein expression of each factor (relative to β-actins, 2 representative bands per group are shown in each figure) was quantified and the average expression (experiments were performed in triplicates) was used for comparisons.
Enzyme-Linked Immunosorbent Assay ET-1 in media from normoxic and hypoxic cells was quantified by ELISA (R&D Systems, Minneapolis, Minn., USA). Furthermore, human VEGF and s-Flt1 ELISAs (R&D Systems, Minneapolis, Minn., USA) were quantified in media from normoxic, hypoxic, and ET antagonist-treated groups. Samples were collected and stored following manufacturer's guidelines. Ninety six-well tray provided with the ELISA was loaded and analyzed following vendors' instructions. Results for VEGF and s-Flt1 were expressed in pg of VEGF or s-Flt1/μg of total protein after 1, 24 and 96 h of hypoxia, whereas for ET-1, results were expressed in pg of ET-1/ μg of total protein after 96 h of hypoxia.
Statistical Analysis
Results are expressed as mean ± SD. Comparisons within groups were performed using paired Student's t test, and among groups using one-way ANOVA. Statistical significance was accepted for p < 0.05.
